PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: Efficacy of imatinib treatment

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 4, 2008, Pages 713-716

  Vigna, Ernesto ^a   Lucia, Eugenio ^a   Gentile, Massimo ^a   Mazzone, Carla ^a   Bisconte, Maria Grazia ^a   Gentile, Carlo ^a   Armentano, Antonio ^b   Ottaviani, Emanuela ^c   Rondoni, Michela ^c   Martinelli, Giovanni ^c   Morabito, Fortunato ^a  

^a Azienda Sanitaria 4   (Italy)

^b Azienda Ospedaliera di Cosenza   (Italy)

^c S Orsola Malpighi Policlinic   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; FIP1 LIKE 1 PROTEIN; GENE PRODUCT; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER LOCALIZATION; CASE REPORT; CHRONIC LEUKEMIA; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DIPLOPIA; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EOSINOPHIL COUNT; EOSINOPHILIC LEUKEMIA; EXOPHTHALMOS; FUSION GENE; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HYPESTHESIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBIT; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; HUMANS; HYPEREOSINOPHILIC SYNDROME; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; ORBITAL NEOPLASMS; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 38049021012     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0507-7     Document Type: Article

References (15)

1. Brito-Babapulle F (2003) The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 121:203-223
2. Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54:1-27
3. Cools J, DeAngelo DJ, Gotlib J et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214
4. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R (2003) Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 100:7830-7835
5. La Starza R, Specchia G, Cuneo A et al (2005) The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/ PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica 90:596-601
6. Roche-Lestienne C, Lepers S, Soenen-Cornu V et al (2005) Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 19:792-798
7. Pardanani A, Brockman SR, Paternoster SF et al (2004) FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104:3038-3045
8. Vandenberghe P, Wlodarska I, Michaux L et al (2004) Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18:734-742
9. Klion AD, Noel P, Akin C et al (2003) Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101:4660-4666
10. Klion AD, Robyn J, Akin C et al (2004) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103:473-478
11. Cortes J, Ault P, Koller C et al (2003) Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101:4714-4716
12. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H (2002) Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26:881-884
13. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359:1577-1578
14. Malagola M, Martinelli G, Rondoni M, Ottavini E, Piccaluga PP, Ricci P, Visani G Baccarani M (2004) Soft tissue and skeletal involvement in FIP1L1-PDGFR-α positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission. Haematological 89(8):ECR25
15. Frickhofen N, Marker-Hermann E, Reiter A, Walz C, Jung B, Bauer H et al (2004) Complete molecular remission af CEL complicated by CNS disease after targeted therapy with imatinib. Annal Hematol 83:477-480